Eric Souied Joins SeaBeLife - Takeaways - MDSpire

Eric Souied Joins SeaBeLife

French biotechnology company, SeaBeLife, welcomes AMD specialist to its scientific committee

  • March 9, 2026

  • 2 min

Share

  • 1

    Professor Eric Souied has joined SeaBeLife's scientific committee to advance its dual-pathway strategy targeting retinal degeneration.

  • 2

    Souied will guide the company's ophthalmology program, focusing on inhibiting necroptosis and ferroptosis in retinal diseases.

  • 3

    SeaBeLife claims its platform uniquely addresses both necroptosis and ferroptosis mechanisms in tandem.

  • 4

    Souied has authored over 650 publications and identified the first genetic polymorphism linked to age-related macular degeneration.

  • 5

    SeaBeLife's lead candidate, SBL03, shows preclinical efficacy in geographic atrophy, affecting an estimated eight million people globally.

Original Source(s)

Eric Souied Joins SeaBeLife

  • March 9, 2026

Related Content

Centre for Sight launches "Eye Health MOT"

New service offers advanced diagnostics, early detection and reassurance

  • February 13, 2026

  • 2 min
Equal Pay in Ophthalmology? Not Yet

A decade of AAMC salary data reveals a persistent gender pay gap in academic ophthalmology—and projects it will never close at senior ranks

Osteoporosis Linked to Increased Dry AMD Risk

Genetic and pooled observational data suggest a unidirectional association, with elevated odds of dry age-related macular degeneration and a stronger signal in women.